首页> 外文期刊>Medical care >An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data
【24h】

An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data

机译:在行政索赔数据中识别转移性乳腺癌,肺癌或结直肠癌的算法的评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background:Administrative health care claims data are used for epidemiologic, health services, and outcomes cancer research and thus play a significant role in policy. Cancer stage, which is often a major driver of cost and clinical outcomes, is not typically included in claims data.Objectives:Evaluate algorithms used in a dataset of cancer patients to identify patients with metastatic breast (BC), lung (LC), or colorectal (CRC) cancer using claims data.Methods:Clinical data on BC, LC, or CRC patients (between January 1, 2007 and March 31, 2010) were linked to a health care claims database. Inclusion required health plan enrollment 3 months before initial cancer diagnosis date. Algorithms were used in the claims database to identify patients' disease status, which was compared with physician-reported metastases. Generic and tumor-specific algorithms were evaluated using ICD-9 codes, varying diagnosis time frames, and including/excluding other tumors. Positive and negative predictive values, sensitivity, and specificity were assessed.Results:The linked databases included 14,480 patients; of whom, 32%, 17%, and 14.2% had metastatic BC, LC, and CRC, respectively, at diagnosis and met inclusion criteria. Nontumor-specific algorithms had lower specificity than tumor-specific algorithms. Tumor-specific algorithms' sensitivity and specificity were 53% and 99% for BC, 55% and 85% for LC, and 59% and 98% for CRC, respectively.Conclusions:Algorithms to distinguish metastatic BC, LC, and CRC from locally advanced disease should use tumor-specific primary cancer codes with 2 claims for the specific primary cancer >30-42 days apart to reduce misclassification. These performed best overall in specificity, positive predictive values, and overall accuracy to identify metastatic cancer in a health care claims database.
机译:背景:行政医疗保健索赔数据用于流行病学,卫生服务和癌症结局研究,因此在政策中起着重要作用。癌症阶段通常是成本和临床结果的主要驱动因素,通常不包括在理赔数据中。目的:评估癌症患者数据集中用于识别患有转移性乳腺癌(BC),肺癌(LC)或癌症的患者的算法方法:将BC,LC或CRC患者的临床数据(2007年1月1日至2010年3月31日之间)链接到医疗保健索赔数据库。纳入要求在最初的癌症诊断日期之前3个月参加健康计划。在索赔数据库中使用了算法来识别患者的疾病状况,并将其与医生报告的转移进行了比较。使用ICD-9代码,不同的诊断时间范围以及包括/排除其他肿瘤来评估通用和特定于肿瘤的算法。结果:所链接的数据库包括14,480名患者;结果显示:其中32%,17%和14.2%在诊断时具有转移性BC,LC和CRC,并符合纳入标准。非肿瘤特异性算法的特异性低于肿瘤特异性算法。肿瘤特异性算法的敏感性和特异性分别为BC的53%和99%,LC的55%和85%以及CRC的59%和98%。结论:区分局部转移性BC,LC和CRC的算法晚期疾病应使用特定于肿瘤的原发性癌代码,并要求间隔> 30-42天的2种特定原发性癌发生率降低错误分类。在医疗保健索赔数据库中,这些药物在特异性,阳性预测值和总体准确性方面表现最佳,可鉴定转移性癌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号